Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody
Methods and compositions for treating inflammatory bowel disease by promoting mucosal healing in the gastrointestinal (GI) tract are encompassed herein. More particularly, methods and compositions described herein relate to agents that activate mononuclear phagocytes (MNPs) in the GI tract and, in turn, regulate the activity of interleukin (IL)-22-producing group 3 innate lymphoid cells (ILC3) in close proximity thereto.
1. A method for treating an inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject a therapeutically effective amount of tumor necrosis factor like ligand 1A (TL1A) or an agent that activates death-domain receptor 3 (DR3), wherein the agent that activates DR3 is an agonistic DR3 antibody, in a composition formulated for oral delivery and to release the TL1A or the agent that activates DR3 in the subject's large intestine, wherein the release of the TL1A or the agent that activates the DR3 in the subject's large intestine promotes mucosal healing in the subject's large intestine, thereby treating IBD in the subject.
2. The method of claim 1 , wherein the IBD is Crohn's Disease (CD) or ulcerative colitis (UC).
3. The method of claim 1 , wherein the composition is formulated to release the TL1A or the agent that activates DR3 at a pH characteristic of the large intestine.
4. The method of claim 3 , wherein the pH is about pH 7.0.
5. The method of claim 1 , wherein the subject is a human.
6. The method of claim 1 , wherein the TL1A is recombinant TL1A.
7. A method for treating an inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject via rectal delivery a therapeutically effective amount of tumor necrosis factor like ligand 1A (TL1A) or an agent that activates death-domain receptor 3 (DR3), wherein the agent that activates DR3 is an agonistic DR3 antibody, or a composition thereof, wherein the TL1A or the agent that activates the DR3 or the composition thereof is administered rectally to promote mucosal healing in the subject's small or large intestine, thereby treating IBD in the subject.
8. The method of claim 7 , wherein the IBD is Crohn's Disease (CD) or ulcerative colitis (UC).
9. The method of claim 7 , wherein the composition is formulated for rectal delivery.
10. The method of claim 9 , wherein the composition formulated for rectal delivery is formulated to release the TL1A or the agent that activates DR3 in the subject's small or large intestine.
11. The method of claim 10 , wherein the composition is formulated to release the TL1A or the agent that activates DR3 at a pH characteristic of the small intestine.
12. The method of claim 11 , wherein the pH is about pH 6.0.
13. The method of claim 10 , wherein the composition is formulated to release the TL1A or the agent that activates DR3 at a pH characteristic of the large intestine.
14. The method of claim 13 , wherein the pH is about pH 7.0.
15. The method of claim 7 , wherein the subject is a human.
16. The method of claim 7 , wherein the TL1A is recombinant TL1A.
17. A method for activating interleukin (IL)-22-producing group 3 innate lymphoid cells (ILC3s) in a subject afflicted with an inflammatory bowel disease (IBD), the method comprising administering to the subject via rectal delivery a therapeutically effective amount of tumor necrosis factor like ligand 1A (TL1A) or an agent that activates death-domain receptor 3 (DR3), wherein the agent that activates DR3 is an agonistic DR3 antibody, or a composition thereof, wherein the TL1A or the agent that activates the DR3 or the composition thereof is administered rectally to activate ILC3s proximal to the intestinal epithelial layer of the subject's large intestine to produce IL-22, thereby promoting mucosal healing in the subject's large intestine.